Value-based healthcare delivery through metabolomics-based personalized health platform

Healthc Manage Forum. 2020 May;33(3):126-134. doi: 10.1177/0840470420904733. Epub 2020 Feb 20.


Type 2 diabetes is routinely identified in clinical practice by tests that rely on a hyperglycemic index. However, people at risk for developing type 2 diabetes may not present with hyperglycemia. We identified several underlying risks for type 2 diabetes, insulin resistance, and associated co-morbidities, using a liquid chromatography mass spectrometry-based analysis of blood metabolites, in participants with normoglycemia and no clinical symptoms. Personalized lifestyle recommendations, including diet, exercise, and nutritional supplement recommendations, were conveyed to these participants by a web-based platform, and after 100 days of following their recommendations, these participants reported reductions in the health risks associated with type 2 diabetes and associated diseases. Our comprehensive metabolite-based assay can be used for type 2 diabetes risk stratification, and our personalized lifestyle recommendation system could be deployed as a preventative treatment option to improve health outcomes, reduce the incidence of chronic disease, and live healthier lives in an evidence-based way.

MeSH terms

  • Biomarkers / blood
  • Blood Glucose
  • Delivery of Health Care*
  • Diabetes Mellitus, Type 2 / therapy
  • Humans
  • Metabolomics*
  • Precision Medicine*
  • Preventive Medicine
  • Value-Based Purchasing*


  • Biomarkers
  • Blood Glucose